Trial intelligence / Profile preview

PLATFORM: Platelet Reactivity-Guided Therapy in STEMI

NCT01739556Phase 3

Key facts

Status: Terminated
Start: Jun 2015
Primary completion: Jan 2018
Countries: 1
Sponsor: University Clinical Center of Serbia
Modality: Small Molecules

Drugs: ticagrelor
Conditions: ST-segment elevation myocardial infarction (STEMI)

Overview

Phase 3, randomised, open-label trial of ticagrelor in ST-segment elevation myocardial infarction (STEMI) (2 arms), sponsored by University Clinical Center of Serbia. Primary endpoint: Major Adverse Cardiovascular Events at 1 year. Started Jun 2015; status: terminated.

Design

2 arms

Study design: RandomizedOpen-label

Intervention Arm
Antiplatelet regimen modification guided by platelet reactivity
Standard Treatment
Standard antiplatelet regimen (Aspirin + Clopidogrel)

Who it enrols

Adult STEMI patients undergoing primary PCI with intermediate to high risk (RISK-PCI score >3), excluding those with high bleeding risk, recent stroke, or active bleeding.

Endpoints

Primary

Major Adverse Cardiovascular Events1 year

Secondary

Total death1 year
Major bleeding1 year
Total bleeding1 year
Reinfarction1 year
Stroke1 year
Revascularisation1 year
Transfusion1 year

Beyond the preview

Go deeper on NCT01739556.

Full results, competitive context and analysis are in the Gosset platform.

Full results & analysis

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01739556.